Showing 1216 Results
A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
The level of consumer cost-sharing for higher cost medication should be aligned with the clinical value – not solely the price – when lower cost alternatives do not produce the desired patient…
NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Assessment Framework
The National Pharmaceutical Council (NPC) today submitted comments to the Institute for Clinical and Economic Review (ICER) about ways to improve its value assessment framework.
Exploring Dynamic Cost-sharing Models in Value-Based Insurance Design
Dr. Mark Fendrick of the Values-Based Insurance Design Center believes there are alternatives to today's static tiered pricing system, instead proposing a dynamic pricing model that acknowledges…
Moving Value Frameworks From Fledgling to Functional
Defining value in health care – especially as our health system shifts its focus from rewarding the volume of services provided to rewarding the value of those services – is complex. It’s going to…
Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.
Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient—has transformed the lives of patients with…
NPC Takes Issue With ICER's Mischaracterization of Funding Sources
To be clear, NPC’s engagement with ICER is not an endorsement of that organization nor its value assessment framework.
Get to Know Our Schaeffer-NPC Postdoctoral Fellow in Health Policy, Dr. Ilene Hollin
The National Pharmaceutical Council (NPC) has partnered with Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California to create a post-doctoral, two-year…
An Interview With Donna Cryer, Global Liver Institute, on Assessing the Value of Treatments for Liver Diseases
Donna Cryer, JD, a liver transplant recipient and founder, president and CEO of the Global Liver Institute, is a passionate advocate for patients. Most recently, she has turned her attention to…
Is CER Having an Impact on Health Care Decision-Making?
In a newly published Journal of Comparative Effectiveness Research commentary, NPC Vice President for Health Services Research Kimberly Westrich highlights the sixth year results of NPC’s annual…
Improving the Exchange of Health Care Economic Data
One area of interest to the National Pharmaceutical Council (NPC) and our member biopharmaceutical companies—and an area we’ve focused on for several years—has been the exchange of evidence to inform…
Formulary Restrictions May Result in Short-Term Savings, But Also Suboptimal Patient Care
Formulary benefits are generally designed with the intention of lowering costs, typically by encouraging the increased use of generic medications and restricting the use of brand medications or other…
Medication Management in ACOs: Are They Ready?
Are accountable care organizations (ACOs) prepared to utilize medications to achieve the best patient health outcomes, while meeting their financial and quality benchmarks? A poster presentation, …